Loss of RESponse to Ustekinumab Treated by Dose Escalation (REScUE)

• ClinicalTrials.gov Identifier: NCT04245215
• Recruitment Status: Recruiting
• First Posted: January 28, 2020
• Last Update Posted: February 25, 2022
• Sponsor: Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW
• Collaborator: Janssen Cilag N.V./S.A.
• Information provided by (Responsible Party): Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW

Study Description

Brief Summary:

The aim of the study is to investigate the effect of re-induction with ustekinumab ≈6mg/kg IV followed by two different maintenance dosing regimens 90 mg subcutaneous every 8 weeks (Q8W) vs 90 mg subcutaneous every 4 weeks(Q4W) on clinical, biological and pharmacological outcomes in patients with Crohn's disease who show a secondary loss of response over time

Condition or disease	Intervention/treatment	Phase
Crohn Disease	Drug: Ustekinumab	Phase 3

Detailed Description:

The study is a prospective double blind interventional study in patients with Crohn Disease treated with ustekinumab that show an objective secondary loss of response to ustekinumab after induction treatment (>Week 16). Patients can be screened during a four week period. The screening includes a clinical, biochemical and endoscopic assessment. Patients will be randomized 8 weeks after the last subcutaneous injection with ustekinumab. All patient will receive an intravenous re-induction with ustekinumab ≈6mg/kg at baseline (8 weeks after last subcutaneous administration). After the intravenous re-induction, the patients receive either ustekinumab 90 mg subcutaneous Q4W or Q8W (altered with q8w placebo to mimic Q4W injections) till week 48. Clinical and biochemical evaluation will be planned every 8 weeks until week36 with a final evaluation at week48. Primary endpoint will be assessed at week 48. Final assessment at week 48 will include clinical, biochemical and endoscopic evaluation.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 108 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: Loss of RESponse to Ustekinumab Treated by Dose Escalation
• Actual Study Start Date: February 13, 2020
• Estimated Primary Completion Date: October 2022
• Estimated Study Completion Date: October 2022

Arms and Interventions

Arm	Intervention/treatment
Placebo Comparator: 1. Subcutaneous ustekinumab every 8 weeks; re-induction (≈6mg/kg) intravenous ustekinumab followed by 90 mg Subcutaneous ustekinumab every 8 weeks (Q8W) for 48 weeks - receiving Q8W placebo to mimic Q4W injections	Drug: Ustekinumab; re-induction and dose escalation form every 8 weeks to every 4 weeks only in arm 2; Other Name: dose escalation only in arm 2
Active Comparator: 2. Subcutaneous ustekinumab every 4 weeks; re-induction (≈6mg/kg) intravenous ustekinumab followed by 90 mg Subcutaneous ustekinumab every 4 weeks (Q4W) for 48 weeks	Drug: Ustekinumab; re-induction and dose escalation form every 8 weeks to every 4 weeks only in arm 2; Other Name: dose escalation only in arm 2

Outcome Measures

Primary Outcome Measures :

1. Proportion of patients with steroid free clinical remission and fecal calprotectin<250µg/g at week 48 [ Time Frame: week 48 ]
   Proportion of patients with steroid free clinical remission (patient reported outcome-2 remission: abdominal pain ≤ 1 AND stool frequency ≤ 3) and fecal calprotectin<250µg/g at week 48. [stool frequency (ST): average number of liquid stools for 1 week abdominal pain (AP): average scoring for abdominal pain for 1 week (0=none; 1=mild, 2=moderate; 3= severe)]

Secondary Outcome Measures :

1. Proportion of patients with complete endoscopic remission at week 48 [ Time Frame: week 48 ]
   Proportion of patients with complete endoscopic remission (simple endoscopic score for Crohn's disease (SES-CD )<3) at week 48
2. Proportion of patients with endoscopic remission at week 48 [ Time Frame: week 48 ]
   Proportion of patients with endoscopic remission (simple endoscopic score for Crohn's disease (SES-CD) <5) at week 48
3. Proportion of patients with endoscopic response at week 48 [ Time Frame: week 48 ]
   Proportion of patients with endoscopic response (≥50% decrease in simple endoscopic score for Crohn's disease (SES-CD)) at week 48
4. Proportion of patients with clinical remission at week 48 [ Time Frame: week 48 ]
   Proportion of patients with clinical remission (patient reported outcome-2 remission: abdominal pain ≤ 1 AND stool frequency ≤ 3) at week 48
5. Proportion of patients with biomarker remission at week 48 [ Time Frame: week 48 ]
   Proportion of patients with biomarker remission (C-reactive protein <5 mg/L and fecal calprotectin <250 µg/g) at week 48
6. Proportion of patients with at all time points after baseline ustekinumab trough concentration > 1.4 μg/mL [ Time Frame: between baseline and week 48 ]
   Proportion of patients with at all time points after baseline ustekinumab trough concentration > 1.4 μg/mL
7. Proportion of patients with serious adverse events at week 48 [ Time Frame: Week 48 ]
   Proportion of patients with serious adverse events at week 48

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. ≥18 years
2. Diagnosis of Crohn's disease by endoscopic and/or radiologic examination.
3. Patient currently treated with ustekinumab, independent of previous biological exposure.
4. Patients treated with maintenance dose of ustekinumab subcutaneous 90 mg every 8 weeks

5. Documented primary response at any time point after induction (week 16) and during maintenance defined as a clinical response (physician discretion) AND confirmed by either any of the following:

   a. if biomarker elevated at start of ustekinumab (C-reactive protein>5 mg/l or fecal calprotectin >250µg/g): i. decrease of C-reactive protein by 50 % or more compared to baseline( prior to ustekinumab induction) ii. C-reactive protein <5 mg/l iii. decrease of fecal calprotectin by 50 % or more compared to baseline( prior to ustekinumab induction) iv. fecal calprotectin<250µg/g b. Documented mucosal healing (simple endoscopic score for Crohn's disease (SES-CD)<3)

6. Documented loss of response after induction (> week 16) assessed by the physician as Moderate to severe active Crohn's disease, defined as Patient Reported Outcome-2 (Abdominal Pain > 1 AND Stool Frequency > 3) AND C-reactive protein and/or fecal calprotectin increased by 25 % or more compared to the lowest value under ustekinumab treatment (C-reactive protein>5 mg/L and/or fecal calprotectin>250µg/g).
7. Presence of mucosal ulcers in at least one segment of the ileum or colon and a simple endoscopic score for Crohn's disease (SES-CD) ≥6 (for patients with isolated ileitis ≥4), as assessed by ileocolonoscopy
8. Adequate contraception in female of reproductive age
9. Have the capacity to understand and sign an informed consent form.
10. Be able to adhere to the study visit schedule and other protocol requirements.

Exclusion Criteria:

1. Ongoing treatment with

   1. other concomitant biological (vedolizumab, anti-TNF)
   2. Steroids >20 mg prednisolone or equivalent at baseline (budesonide >6 mg)
   3. Patient already receiving ustekinumab every 4 weeks
2. Women that are pregnant, nursing, or planning pregnancy

3. Have screening laboratory test results within the following parameters:

   1. Haemoglobin < 8.5 g/dL
   2. Platelets < 100,000 /mm3
   3. Serum creatinine ≥ 1.7 mg/dL
   4. aspartate aminotransferase and alanine aminotransferase > 3 times the upper limit of normal range
   5. Direct (conjugated) bilirubin ≥ 3.0 mg/dL.
4. Have current signs or symptoms of infection confirmed by positive stool or blood testing (including gastrointestinal pathogens, tuberculosis, human immunodeficiency virus, hepatitis B, hepatitis C).
5. Patients with a positive stool sample for gastrointestinal pathogen including Clostridium difficile.
6. Evidence of current or previous clinically significant disease, medical condition other than Crohn's Disease, finding of the medical examination, or laboratory value at the screening visit outside the reference range that is of clinical relevance, that in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data.
7. Patients with an ileostomy
8. Patients that received an intravenous re-induction with ustekinumab within the 6 months prior to baseline.
9. Patients with an impassable stenosis even after attempt of endoscopic balloon dilation.
10. Patients with an abscess

Contacts and Locations

Contacts

Contact: Ingrid V Arijs; +32499317005 ext +320499566221; ingrid.arijs@birdgroup.be

Locations

Belgium

Ingrid Arijs; Recruiting

Zaventem, Belgium, 1930

Contact: Ingrid V Arijs, PhD +32499317005 ingrid.arijs@birdgroup.be

Sponsors and Collaborators

Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW

Janssen Cilag N.V./S.A.

Investigators

• Principal Investigator: Peter Bossuyt, MD; BIRD (Belgian IBD Research and Development) vzw

More Information

• Responsible Party: Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW
• ClinicalTrials.gov Identifier: NCT04245215
• Other Study ID Numbers: BIRD2018001
• First Posted: January 28, 2020
• Last Update Posted: February 25, 2022
• Last Verified: February 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No

Keywords provided by Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW:

dose escalation; ustekinumab

Additional relevant MeSH terms:

Crohn Disease; Inflammatory Bowel Diseases; Gastroenteritis; Gastrointestinal Diseases; Digestive System Diseases; Intestinal Diseases; Ustekinumab; Dermatologic Agents